Prevention of angiogenesis by naked DNA IL-12 gene transfer: Angioprevention by immunogene therapy

M. Morini, A. Albini, G. Lorusso, K. Moelling, B. Lu, M. Cilli, S. Ferrini, D. M. Noonan

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

IL-12 is thought to induce a cytokine cascade with antiangiogenic effects mediated by IFN-γ and angiostatic CXCR3 chemokine ligands. Naked DNA intramuscular injection of an expression vector plasmid producing IL-12 resulted in significant, well-tolerated elevation of serum IL-12 levels. Injection of the IL-12 plasmid at least 2 days, and up to 20 days, before subcutaneous injection of matrigel with angiogenic factors resulted in strong prevention of angiogenesis in both C57/bl and nude mice. A single injection of the IL-12 plasmid contemporarily with the matrigel or 2 days after resulted in partial, statistically not significant, inhibition. Control plasmid injection did not affect either angiogenesis or angiogenesis inhibition by IL-12 protein in vivo. Angiogenesis inhibition was observed in NK cell-depleted C57/bl and nude mice as well as in IFN-γ-/- and CXCR3-/- knockout mice, indicating that NK- and/or T-cell-initiated IFN-γ- chemokine cascades were not involved in the angiogenesis inhibition observed in vivo. Finally, IL-12 plasmid DNA gene transfer significantly prevented the growth and vascularization of highly angiogenic KS-Imm Kaposi's sarcoma and TS/A murine mammary carcinoma tumors in nude and/or syngeneic mice. These data suggest that a preventive gene therapy approach using antiangiogenic cytokines can effectively inhibit tumor angiogenesis and KS, representing an example of angioimmunoprevention.

Original languageEnglish
Pages (from-to)284-291
Number of pages8
JournalGene Therapy
Volume11
Issue number3
DOIs
Publication statusPublished - Feb 2004

Fingerprint

Interleukin-12
Plasmids
DNA
Genes
Chemokines
Nude Mice
Therapeutics
Injections
Breast Neoplasms
Cytokines
Angiogenesis Inducing Agents
Kaposi's Sarcoma
Intramuscular Injections
Subcutaneous Injections
Knockout Mice
Natural Killer Cells
Genetic Therapy
Ligands
T-Lymphocytes
Growth

Keywords

  • Interferon gamma
  • Interleukin-12
  • Kaposi's sarcoma
  • Naked DNA
  • Tumor angiogenesis

ASJC Scopus subject areas

  • Genetics

Cite this

Prevention of angiogenesis by naked DNA IL-12 gene transfer : Angioprevention by immunogene therapy. / Morini, M.; Albini, A.; Lorusso, G.; Moelling, K.; Lu, B.; Cilli, M.; Ferrini, S.; Noonan, D. M.

In: Gene Therapy, Vol. 11, No. 3, 02.2004, p. 284-291.

Research output: Contribution to journalArticle

Morini, M. ; Albini, A. ; Lorusso, G. ; Moelling, K. ; Lu, B. ; Cilli, M. ; Ferrini, S. ; Noonan, D. M. / Prevention of angiogenesis by naked DNA IL-12 gene transfer : Angioprevention by immunogene therapy. In: Gene Therapy. 2004 ; Vol. 11, No. 3. pp. 284-291.
@article{98aa91aef3624274aff3cc19d47cdecb,
title = "Prevention of angiogenesis by naked DNA IL-12 gene transfer: Angioprevention by immunogene therapy",
abstract = "IL-12 is thought to induce a cytokine cascade with antiangiogenic effects mediated by IFN-γ and angiostatic CXCR3 chemokine ligands. Naked DNA intramuscular injection of an expression vector plasmid producing IL-12 resulted in significant, well-tolerated elevation of serum IL-12 levels. Injection of the IL-12 plasmid at least 2 days, and up to 20 days, before subcutaneous injection of matrigel with angiogenic factors resulted in strong prevention of angiogenesis in both C57/bl and nude mice. A single injection of the IL-12 plasmid contemporarily with the matrigel or 2 days after resulted in partial, statistically not significant, inhibition. Control plasmid injection did not affect either angiogenesis or angiogenesis inhibition by IL-12 protein in vivo. Angiogenesis inhibition was observed in NK cell-depleted C57/bl and nude mice as well as in IFN-γ-/- and CXCR3-/- knockout mice, indicating that NK- and/or T-cell-initiated IFN-γ- chemokine cascades were not involved in the angiogenesis inhibition observed in vivo. Finally, IL-12 plasmid DNA gene transfer significantly prevented the growth and vascularization of highly angiogenic KS-Imm Kaposi's sarcoma and TS/A murine mammary carcinoma tumors in nude and/or syngeneic mice. These data suggest that a preventive gene therapy approach using antiangiogenic cytokines can effectively inhibit tumor angiogenesis and KS, representing an example of angioimmunoprevention.",
keywords = "Interferon gamma, Interleukin-12, Kaposi's sarcoma, Naked DNA, Tumor angiogenesis",
author = "M. Morini and A. Albini and G. Lorusso and K. Moelling and B. Lu and M. Cilli and S. Ferrini and Noonan, {D. M.}",
year = "2004",
month = "2",
doi = "10.1038/sj.gt.3302175",
language = "English",
volume = "11",
pages = "284--291",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Prevention of angiogenesis by naked DNA IL-12 gene transfer

T2 - Angioprevention by immunogene therapy

AU - Morini, M.

AU - Albini, A.

AU - Lorusso, G.

AU - Moelling, K.

AU - Lu, B.

AU - Cilli, M.

AU - Ferrini, S.

AU - Noonan, D. M.

PY - 2004/2

Y1 - 2004/2

N2 - IL-12 is thought to induce a cytokine cascade with antiangiogenic effects mediated by IFN-γ and angiostatic CXCR3 chemokine ligands. Naked DNA intramuscular injection of an expression vector plasmid producing IL-12 resulted in significant, well-tolerated elevation of serum IL-12 levels. Injection of the IL-12 plasmid at least 2 days, and up to 20 days, before subcutaneous injection of matrigel with angiogenic factors resulted in strong prevention of angiogenesis in both C57/bl and nude mice. A single injection of the IL-12 plasmid contemporarily with the matrigel or 2 days after resulted in partial, statistically not significant, inhibition. Control plasmid injection did not affect either angiogenesis or angiogenesis inhibition by IL-12 protein in vivo. Angiogenesis inhibition was observed in NK cell-depleted C57/bl and nude mice as well as in IFN-γ-/- and CXCR3-/- knockout mice, indicating that NK- and/or T-cell-initiated IFN-γ- chemokine cascades were not involved in the angiogenesis inhibition observed in vivo. Finally, IL-12 plasmid DNA gene transfer significantly prevented the growth and vascularization of highly angiogenic KS-Imm Kaposi's sarcoma and TS/A murine mammary carcinoma tumors in nude and/or syngeneic mice. These data suggest that a preventive gene therapy approach using antiangiogenic cytokines can effectively inhibit tumor angiogenesis and KS, representing an example of angioimmunoprevention.

AB - IL-12 is thought to induce a cytokine cascade with antiangiogenic effects mediated by IFN-γ and angiostatic CXCR3 chemokine ligands. Naked DNA intramuscular injection of an expression vector plasmid producing IL-12 resulted in significant, well-tolerated elevation of serum IL-12 levels. Injection of the IL-12 plasmid at least 2 days, and up to 20 days, before subcutaneous injection of matrigel with angiogenic factors resulted in strong prevention of angiogenesis in both C57/bl and nude mice. A single injection of the IL-12 plasmid contemporarily with the matrigel or 2 days after resulted in partial, statistically not significant, inhibition. Control plasmid injection did not affect either angiogenesis or angiogenesis inhibition by IL-12 protein in vivo. Angiogenesis inhibition was observed in NK cell-depleted C57/bl and nude mice as well as in IFN-γ-/- and CXCR3-/- knockout mice, indicating that NK- and/or T-cell-initiated IFN-γ- chemokine cascades were not involved in the angiogenesis inhibition observed in vivo. Finally, IL-12 plasmid DNA gene transfer significantly prevented the growth and vascularization of highly angiogenic KS-Imm Kaposi's sarcoma and TS/A murine mammary carcinoma tumors in nude and/or syngeneic mice. These data suggest that a preventive gene therapy approach using antiangiogenic cytokines can effectively inhibit tumor angiogenesis and KS, representing an example of angioimmunoprevention.

KW - Interferon gamma

KW - Interleukin-12

KW - Kaposi's sarcoma

KW - Naked DNA

KW - Tumor angiogenesis

UR - http://www.scopus.com/inward/record.url?scp=1242296137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242296137&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302175

DO - 10.1038/sj.gt.3302175

M3 - Article

C2 - 14737088

AN - SCOPUS:1242296137

VL - 11

SP - 284

EP - 291

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 3

ER -